Looking for information about AUSPEX PHARMACEUTICALS HEADQUARTERS? Follow the links below to find all the information you are interested in. Addresses, telephones, emails, working hours and other useful information.


Auspex Pharmaceuticals - Crunchbase Company Profile & Funding

    https://www.crunchbase.com/organization/auspex-pharmaceuticals
    Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardiveFounded: 2001

Auspex Pharmaceuticals Company Profile: Acquisition ...

    https://pitchbook.com/profiles/company/13413-79
    Auspex Pharmaceuticals General Information Description. Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that improves on existing drugs across various therapeutic areas.

Auspex Pharmaceuticals Inc - Company Profile and News ...

    https://www.bloomberg.com/profile/company/ASPX:US
    Auspex Pharmaceuticals, Inc. operates as a biopharmaceutcial company. The Company develops and distributes novel medicines for the treatment of orphan diseases.Employees: 35

Meet the Company – HD Insights - Huntington Study Group

    https://huntingtonstudygroup.org/hd-insights/meet-the-company-3/
    Feb 13, 2014 · NAME: Auspex Pharmaceuticals. HEADQUARTERS: La Jolla, CA. STOCK PRICE AS OF 2/13/2014: $22.20. MARKET CAPITALIZATION: $478 M. EMPLOYEES: about 20. Pratik Shah, PhD, MBA, is the President, Chief Executive Officer, and Director of Auspex Pharmaceuticals. He came to Auspex in 2007 as an investor, and has since led the company as Chairman or ...

Auspex Pharmaceuticals EquityNet

    https://www.equitynet.com/c/auspex-pharmaceuticals
    Auspex Pharmaceuticals, Inc., a deuteration company, engages in developing a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. The company focuses on developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of depressive disorders. The company was founded in 2001 and is based in Vista, California.

In addition to information on AUSPEX PHARMACEUTICALS HEADQUARTERS, our site contains many other interesting information about corporate offices. We invite you to view the pages with related information.

Related Corporate Office Information: